Bernard Zinman

98.4k total citations · 32 hit papers
652 papers, 63.6k citations indexed

About

Bernard Zinman is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Bernard Zinman has authored 652 papers receiving a total of 63.6k indexed citations (citations by other indexed papers that have themselves been cited), including 441 papers in Endocrinology, Diabetes and Metabolism, 215 papers in Surgery and 168 papers in Molecular Biology. Recurrent topics in Bernard Zinman's work include Diabetes Treatment and Management (314 papers), Diabetes Management and Research (201 papers) and Pancreatic function and diabetes (165 papers). Bernard Zinman is often cited by papers focused on Diabetes Treatment and Management (314 papers), Diabetes Management and Research (201 papers) and Pancreatic function and diabetes (165 papers). Bernard Zinman collaborates with scholars based in Canada, United States and Germany. Bernard Zinman's co-authors include John M. Lachin, John B. Buse, Ravi Retnakaran, Silvio E. Inzucchi, Christoph Wanner, Anthony J. Hanley, Odd Erik Johansen, David Fitchett, Rury R. Holman and Michaela Mattheus and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Bernard Zinman

637 papers receiving 61.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2015 8.1k citations Bernard Zinman, Christoph Wanner et al. profile →
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

2016 4.9k citations Johannes F.E. Mann, Bernard Zinman et al. profile →
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

2008 3.0k citations Bernard Zinman et al. Diabetes Care profile →
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

2016 2.6k citations Christoph Wanner, Silvio E. Inzucchi et al. profile →
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 2.2k citations Steven E. Kahn, John M. Lachin et al. profile →
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

2017 1.5k citations Bernard Zinman et al. profile →
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

2006 1.2k citations Hertzel C. Gerstein, Bernard Zinman et al. profile →
Impaired Fasting Glucose and Impaired Glucose Tolerance

2007 1.1k citations Bernard Zinman et al. Diabetes Care profile →
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

2006 918 citations Bernard Zinman et al. Diabetes Care profile →
Liraglutide and Renal Outcomes in Type 2 Diabetes

2017 859 citations Johannes F.E. Mann, Bernard Zinman et al. profile →
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

2018 756 citations Julio Rosenstock, Vlado Perkovic et al. profile →
Are Metabolically Healthy Overweight and Obesity Benign Conditions?

2013 711 citations Caroline K. Kramer, Bernard Zinman et al. profile →
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

2009 707 citations Bernard Zinman et al. Diabetes Care profile →
Diabetic Retinopathy and Diabetic Macular Edema

2003 650 citations Bernard Zinman et al. Diabetes Care profile →
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

2008 543 citations Bernard Zinman et al. profile →
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

2017 526 citations Silvio E. Inzucchi, Bernard Zinman et al. Diabetes Care profile →
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes

2009 514 citations Bernard Zinman et al. profile →
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

2017 413 citations Bernard Zinman et al. profile →
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

2017 409 citations Darren K. McGuire, Bernard Zinman et al. profile →
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

2019 394 citations Julio Rosenstock, Steven E. Kahn et al. profile →
Type 1 Diabetes Mellitus and Cardiovascular Disease

2014 394 citations Ian H. de Boer, Nikolaus Marx et al. Circulation profile →
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

2019 386 citations Bernard Zinman et al. Circulation profile →
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

2017 340 citations Christoph Wanner, John M. Lachin et al. Circulation profile →
Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality

2015 303 citations Bernard Zinman, John M. Lachin et al. profile →
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

2017 287 citations Bernard Zinman, Silvio E. Inzucchi et al. profile →
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum

2017 275 citations Hertzel C. Gerstein, Bernard Zinman et al. Diabetes Care profile →
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019 267 citations Bernard Zinman et al. profile →
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

2018 244 citations Julio Rosenstock, Bernard Zinman et al. Diabetes Care profile →
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

2019 243 citations Silvio E. Inzucchi, Darren K. McGuire et al. Circulation profile →
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

2021 161 citations Johannes F.E. Mann, Bernard Zinman et al. Circulation profile →
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

2022 134 citations Bernard Zinman et al. profile →
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

2023 120 citations Steven E. Kahn, Darren K. McGuire et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Zinman Canada	106	44.5k	18.6k	18.0k	8.9k	7.3k	652	63.6k
David R. Matthews United Kingdom	81	44.0k 1.0×	18.3k 1.0×	16.3k 0.9×	10.1k 1.1×	13.9k 1.9×	272	75.4k
Steven M. Haffner United States	125	33.2k 0.7×	11.2k 0.6×	11.1k 0.6×	14.9k 1.7×	11.4k 1.6×	518	62.2k
Hertzel C. Gerstein Canada	94	26.6k 0.6×	8.8k 0.5×	8.1k 0.5×	12.3k 1.4×	7.6k 1.0×	505	51.2k
Ele Ferrannini Italy	107	29.1k 0.7×	15.2k 0.8×	13.3k 0.7×	7.0k 0.8×	11.9k 1.6×	535	51.5k
Markku Laakso Finland	117	23.4k 0.5×	16.3k 0.9×	11.7k 0.6×	13.0k 1.5×	13.5k 1.8×	673	58.2k
Gerald M. Reaven United States	109	30.5k 0.7×	13.6k 0.7×	10.3k 0.6×	11.2k 1.3×	19.1k 2.6×	666	59.5k
Ralph A. DeFronzo United States	113	24.6k 0.6×	21.0k 1.1×	12.0k 0.7×	4.3k 0.5×	17.7k 2.4×	427	52.3k
Steven E. Kahn United States	105	21.1k 0.5×	12.7k 0.7×	12.9k 0.7×	4.8k 0.5×	13.3k 1.8×	471	46.7k
Ralph A. DeFronzo United States	88	19.4k 0.4×	13.5k 0.7×	8.1k 0.5×	4.3k 0.5×	11.9k 1.6×	284	38.6k
Juliana C.N. Chan Hong Kong	87	18.0k 0.4×	7.9k 0.4×	5.9k 0.3×	5.3k 0.6×	5.1k 0.7×	849	39.5k

Countries citing papers authored by Bernard Zinman

Since Specialization

Citations

This map shows the geographic impact of Bernard Zinman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Zinman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Zinman more than expected).

Fields of papers citing papers by Bernard Zinman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Zinman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Zinman. The network helps show where Bernard Zinman may publish in the future.

Co-authorship network of co-authors of Bernard Zinman

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Zinman. A scholar is included among the top collaborators of Bernard Zinman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Zinman. Bernard Zinman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Retnakaran, Ravi, Chang Ye, Anthony J. Hanley, et al.. (2023). Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy. Diabetes Care. 46(3). 587–592. 9 indexed citations

Ye, Chang, Anthony J. Hanley, Philip W. Connelly, et al.. (2023). Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy. Diabetes Obesity and Metabolism. 26(4). 1207–1215. 1 indexed citations

Retnakaran, Ravi, et al.. (2023). Future cardiometabolic implications of insulin hypersecretion in response to oral glucose: a prospective cohort study. EClinicalMedicine. 67. 102363–102363. 4 indexed citations

Retnakaran, Ravi, Stewart B. Harris, Sonja M. Reichert, et al.. (2023). Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. Nature Communications. 14(1). 4514–4514. 13 indexed citations

Retnakaran, Ravi, Chang Ye, Anthony J. Hanley, et al.. (2022). Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life. Diabetes Care. 45(5). 1230–1238. 6 indexed citations

Boyko, Edward J., Leila R. Zelnick, Barbara H. Braffett, et al.. (2022). Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 45(2). 357–364. 50 indexed citations

Retnakaran, Ravi, Chang Ye, Stewart B. Harris, et al.. (2021). Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes ( RESET‐IT Main ): A 2‐year randomized controlled trial. Diabetes Obesity and Metabolism. 23(8). 1926–1935. 11 indexed citations

Butcher, James, Sylvia H. Ley, Anthony J. Hanley, et al.. (2020). Examining the relationship between maternal body size, gestational glucose tolerance status, mode of delivery and ethnicity on human milk microbiota at three months post-partum. BMC Microbiology. 20(1). 219–219. 27 indexed citations

Perkovic, Vlado, Robert D. Toto, Mark E. Cooper, et al.. (2020). Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 43(8). 1803–1812. 42 indexed citations

10.

McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations

11.

Volpe, Alessandro, Ye Rim Chang, Anthony J. Hanley, et al.. (2019). Changes Over Time in Uric Acid in Relation to Changes in Insulin Sensitivity, Beta-Cell Function, and Glycemia. The Journal of Clinical Endocrinology & Metabolism. 105(3). e651–e659. 15 indexed citations

12.

Semnani‐Azad, Zhila, Philip W. Connelly, Ravi Retnakaran, et al.. (2019). The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function. The Journal of Clinical Endocrinology & Metabolism. 105(3). e285–e294. 11 indexed citations

13.

Semnani‐Azad, Zhila, Christine Lee, Ravi Retnakaran, et al.. (2019). Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. BMJ Open Diabetes Research & Care. 7(1). e000825–e000825. 16 indexed citations

14.

Retnakaran, Ravi, Haysook Choi, Chang Ye, Caroline K. Kramer, & Bernard Zinman. (2018). Two‐year trial of intermittent insulin therapy vs metformin for the preservation of β‐cell function after initial short‐term intensive insulin induction in early type 2 diabetes. Diabetes Obesity and Metabolism. 20(6). 1399–1407. 14 indexed citations

15.

Wanner, Christoph, John M. Lachin, Silvio E. Inzucchi, et al.. (2017). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 137(2). 119–129. 340 indexed citations breakdown →

16.

Souza, Leanne R. De, Chang Ye, Anthony J. Hanley, et al.. (2017). Circulating B‐type natriuretic peptide in women with and without recent gestational diabetes: The impact of current glucose intolerance. Clinical Endocrinology. 88(2). 227–233. 3 indexed citations

17.

Purnell, Jonathan Q., Bernard Zinman, & John D. Brunzell. (2012). The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus. Circulation. 127(2). 180–187. 192 indexed citations

18.

Matthäei, S., et al.. (2007). Raising diabetes awareness in the public domain. International Journal of Clinical Practice. 61(157). 31–37. 7 indexed citations

19.

Sharma, Sangita, Xia Cao, Joel Gittelsohn, et al.. (2007). Dietary intake and development of a quantitative food-frequency questionnaire for a lifestyle intervention to reduce the risk of chronic diseases in Canadian First Nations in north-western Ontario. Public Health Nutrition. 11(8). 831–840. 32 indexed citations

20.

Pollex, Rebecca L., Anthony J. Hanley, Bernard Zinman, et al.. (2005). Synergism between mutant HNF1A and the metabolic syndrome in Oji‐Cree Type 2 diabetes. Diabetic Medicine. 22(11). 1510–1515. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact